Abpro Holdings (ABPO) Total Current Liabilities (2021 - 2026)
Abpro Holdings' (ABPO) quarterly Total Current Liabilities came in at $9.1 million in Q1 2026, down 55.76% YoY from $20.6 million in Q1 2025, and down 2.44% on a QoQ basis from $9.3 million in Q4 2025.
Abpro Holdings (ABPO) Total Current Liabilities (2021 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 6 years of Total Current Liabilities data on file, last reported at $9.1 million in Q1 2026.
- Quarterly Total Current Liabilities fell 55.76% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (down 55.76% YoY) and the FY2025 annual result came in at $9.3 million, down 52.34% from the prior year.
- Total Current Liabilities fell to $9.1 million in Q1 2026, from $9.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $20.6 million in Q1 2025 to a low of $390037.0 in Q1 2022.
- A 5-year average of $9.1 million and a median of $7.3 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities surged 853.1% — and 2026, when it tumbled 55.76%.
- Tracing ABPO's Total Current Liabilities over 5 years: stood at $2.1 million in 2022, then surged by 634.58% to $15.7 million in 2023, then increased by 24.6% to $19.6 million in 2024, then tumbled by 52.34% to $9.3 million in 2025, then declined by 2.44% to $9.1 million in 2026.
- The last three Total Current Liabilities figures came in at $9.1 million (Q1 2026), $9.3 million (Q4 2025), and $17.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | 8.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.12 Mn |
| Dec 31, 2025 | 9.35 Mn |
| Sep 30, 2025 | 17.30 Mn |
| Jun 30, 2025 | 20.43 Mn |
| Mar 31, 2025 | 20.61 Mn |
| Dec 31, 2024 | 19.61 Mn |
| Sep 30, 2024 | 9.04 Mn |
| Jun 30, 2024 | 7.31 Mn |
| Mar 31, 2024 | 6.61 Mn |
| Dec 31, 2023 | 15.74 Mn |
| Sep 30, 2023 | 5.51 Mn |
| Jun 30, 2023 | 6.39 Mn |
| Mar 31, 2023 | 3.16 Mn |
| Dec 31, 2022 | 2.14 Mn |
| Sep 30, 2022 | 1.26 Mn |
| Jun 30, 2022 | 670,177.00 |
| Mar 31, 2022 | 390,037.00 |
| Dec 31, 2021 | 338,165.00 |